LIGAND PHARMACEUTICALS INC Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD from Q1 2019 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Ligand Pharmaceuticals Inc quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount history and growth rate from Q1 2019 to Q4 2023.
  • Ligand Pharmaceuticals Inc Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending December 31, 2023 was $2.24M, a 48.9% decline year-over-year.
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $2.24M -$2.14M -48.9% Dec 31, 2023 10-K 2024-02-29
Q4 2022 $4.38M +$355K +8.82% Dec 31, 2022 10-K 2023-02-28
Q3 2022 $10.5M +$7.63M +266% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $6.74M Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $3.86M Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $4.03M +$2.89M +256% Dec 31, 2021 10-K 2022-02-28
Q3 2021 $2.86M Sep 30, 2021 10-Q 2021-11-09
Q4 2020 $1.13M -$1.52M -57.4% Dec 31, 2020 10-K 2021-02-24
Q4 2019 $2.65M Dec 31, 2019 10-K 2020-02-27
Q3 2019 $2.73M Sep 30, 2019 10-Q 2019-11-08
Q2 2019 $2.86M Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $1.38M Mar 31, 2019 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.